167834-56-2

Upstream product

• 826-81-3 2-methyl-8-quinolinol 
• 7732-18-5 water 
• 83141-02-0 2-bromomethyl-1,3-dichloro-4-nitro-benzene 
• 115310-98-0 8-hydroxy-2,4-dimethylquinoline 
• 179625-77-5 2,6-dimethyl-1-methanesulfonyloxymethyl-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene 
• 179627-10-2 2-methylquinoline-8-carbamic acid tert-butyl ester 
• 167837-50-5 2-methyl-8-hydroxyquinoxaline 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 29682-46-0 2,6-dichloro-3-nitrotoluene 

Downstream Products

• 617721-43-4 C₁₇H₁₃Cl₃N₂O 
• 189268-49-3 1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)phenyl]-2-[(E)-3-(6-ethoxycarbonylpyridin-3-yl)acryloylaminomethyl]pyrrole 
• 189268-50-6 2-[(E)-3-(6-carboxypyridin-3-yl)acryloylaminomethyl]-1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)phenyl]pyrrole 
• 189268-39-1 2-aminomethyl-1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)phenyl]pyrrole 
• 189268-37-9 1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)-phenyl]-2-cyanopyrrole 
• 179621-82-0 8-[2,6-dichloro-3-glycylaminobenzyloxy]-2-methylquinoline 
• 189268-35-7 1-[2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)-phenyl]pyrrole 
• 213988-16-0 2-amino-N-methyl-N-[3-(2-methyl-quinolin-8-yloxymethyl)-2,4-bis-methylsulfanyl-phenyl]-acetamide 
• 213988-13-7 3-(2-methyl-quinolin-8-yloxymethyl)-2,4-bis-methylsulfanyl-phenylamine 
• 167834-66-4 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline 
• 213988-12-6 8-(2,6-bis-methylsulfanyl-3-nitro-benzyloxy)-2-methyl-quinoline 
• 179625-53-7 8-(2,6-dichloro-3-aminobenzyloxy)-2-methylquinoline 

Relevant academic research and scientific papers

Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk

Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, process for their preparation, and their use

Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, process or their preparation, and their useHeterocyclic fluoroalkyl derivatives and fluoroalkoxy derivatives of the formula (I) having bradykinin-antagonistic action STR1 in wh

Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors

The synthesis and the SAR study of novel O-substituted 8-quinolines and 4-benzothiazoles as highly potent non-peptide bradykinin B2 receptor antagonists are described. Several members of this series of antagonists efficiently inhibited the BK-induced vasoconstriction on different isolated organ preparations.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation

In recent articles we reported the identification of a series of 8- [[2,6-dichloro-3-[N-methyl-N-[(E)- (substituted)acryloylglycyl]amino]benzyl]oxy]-2-methylimidazo[1,2- a]pyridines as the first orally active non-peptide bradykinin (BK) B2 rece

BRADYKININ ANTAGONIST QUINOLINES

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin-or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.